• Sun Pharmaceutical Industries Ltd, India’s largest revenue-generating drugmaker, has announced the appointment of Kirti Ganorkar as Managing Director effective September 1, 2025 .
• Founder Dilip Shanghvi will transition into the role of Executive Chairman, pending shareholder approval at the AGM scheduled for July 31 .

👨‍💼 Kirti Ganorkar – Experience & Vision:

• Joined Sun Pharma in 1996 and has led the India business since June 2019, driving consistent market share and revenue growth .
• Played strategic roles in specialty drug launches (including Ilumya), geographic expansion (Japan, Europe), and led multiple functions like marketing, M&A, IP & litigation .
• Holds a chemical engineering degree and an MBA, having undertaken multi-domain leadership within the company.

🌍 North America Leadership Update:

• Abhay Gandhi, CEO for North America and a 30-year veteran, is leaving. He will be succeeded by Richard Ascroft, reporting to COO Aalok Shanghvi .

🔑 Strategic Significance:

• The succession reveals Sun Pharma’s robust internal talent pipeline and structured leadership transition commitment.
• Dilip Shanghvi’s new role will allow focused efforts on expanding the company’s specialty portfolio and long-term innovation direction .

The post Sun Pharma Appoints Kirti Ganorkar as Managing Director in Major Leadership Shift appeared first on Mission Ki Awaaz.